

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Shanghai Haohai Biological Technology Co., Ltd.\***

**上海昊海生物科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6826)**

### **RE-DESIGNATION OF EXECUTIVE DIRECTOR**

**AND**

### **CHANGE OF BOARD SECRETARY AND PROPOSED CHANGE OF JOINT COMPANY SECRETARY**

#### **1. RE-DESIGNATION OF EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Shanghai Haohai Biological Technology Co., Ltd.\* (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Huang Ming (“**Mr. Huang**”) has been re-designated as a non-executive Director from an executive Director with effect from 19 December 2019.

#### **2. CHANGE OF BOARD SECRETARY AND PROPOSED CHANGE OF JOINT COMPANY SECRETARY**

The Board of the Company announces that Mr. Huang will cease to act as the Board secretary with effect from 19 December 2019, and as a joint company secretary of the Company with effect from 1 January 2020 or the date on which the Company receives the waiver letter from The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) in respect of the newly appointed joint company secretary, whichever is later.

Mr. Huang’s resignation from the aforesaid positions is due to his arrangement of work commitment. Mr. Huang confirmed that he has no disagreement with the Board and there are no circumstances related to his resignation which need to be brought to the attention of the Hong Kong Stock Exchange and the shareholders of the Company.

During his tenure as the Board secretary and a joint company secretary of the Company, Mr. Huang performed his duties diligently and conscientiously, and completed the initial offering and listing of H shares of the Company on the Main Board of the Hong Kong Stock Exchange and A shares of the Company on the Sci-tech Innovation Board of the Shanghai Stock Exchange. The Board would like to express its satisfaction with the work done by Mr. Huang, its high appreciation and sincere gratitude for his contributions to the development of the Company.

The Board also announces that Ms. Tian Min (“**Ms. Tian**”) will be appointed as the Board secretary and a joint company secretary. Ms. Tian will serve as the Board secretary with effect from 19 December 2019. The proposed appointment of Ms. Tian as the joint company secretary of the Company shall be subject to the approval granted by the Hong Kong Stock Exchange in respect of a waiver from strict compliance with Rules 3.28 and 8.17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Listing Rules**”), and will take effect on 1 January 2020 or when the Company receives the waiver letter from the Hong Kong Stock Exchange, whichever is later. The Company has applied such waiver with the Hong Kong Stock Exchange and will separately make announcement to further update the progress of obtaining of such approval.

## **BIOGRAPHICAL DETAILS OF MR. HUANG**

Mr. Huang, aged 44, has been appointed as a Director since July 2010 and was re-designated as an executive Director on 7 December 2014. Since joining the Group in 2007, Mr. Huang has also been serving as a director or a supervisor of several subsidiaries of the Company. Mr. Huang obtained a bachelor of laws in July 1998 and a master of laws in June 2005 from East China University of Political Science and Law, and a doctoral degree in corporate management from Fudan University in June 2011. He obtained his lawyer qualification in May 1999.

To the best of the knowledge of the Directors and save as disclosed above, Mr. Huang did not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years. Mr. Huang has no relationship with any Directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company.

As at the date of this announcement, for the purpose of Part XV of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong) (the “**SFO**”), Mr. Huang is interested in 2,000,000 A shares of the Company. Mr. Huang’s emolument is determined by the Board based on the authorization by the general meeting of the Company taking into account, among other factors, the prevailing market rate, the Company’s remuneration policy, and his duties with the Group and contribution to the Group.

Save as disclosed above, Mr. Huang has confirmed that there is no other information or matters in relation to his re-designation that is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Hong Kong Listing Rules, nor are there any other matters that need to be brought to the attention of the shareholders of the Company.

## **BIOGRAPHICAL DETAILS OF MS. TIAN**

Ms. Tian joined the Group in July 2015 working in the office of the Board of the Group and is currently the representative of the Company's Securities Affairs, primarily responsible for financial reporting and investor relations of the Company. Throughout her employment with the Company, Ms. Tian has been involved in, among other things, financial reporting matters and the preparation of the Company's regulatory announcements and circulars. Ms. Tian has obtained the qualification certificate from the Shanghai Stock Exchange for serving as the Board secretary in July 2019. Her qualifications are in compliance with the requirements under relevant laws, regulations and rules, including the Company Law of the People's Republic of China (the "PRC") and the Rules Governing the Listing of Shares on the Sci-tech Innovation Board of the Shanghai Stock Exchange, and have been approved by the Shanghai Stock Exchange without objection therefrom. Ms. Tian obtained the PRC Legal Profession Qualification Certificate awarded by the Ministry of Justice of the PRC in March 2014. Ms. Tian obtained a master of laws degree from the East China University of Political Science and Law in July 2015.

By order of the Board  
**Shanghai Haohai Biological Technology Co., Ltd.\***  
*Chairman*  
**Hou Yongtai**

Shanghai, the PRC, 19 December 2019

*As at the date of this announcement, the executive Directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive Directors of the Company are Ms. You Jie and Mr. Huang Ming; and the independent non-executive Directors of the Company are Mr. Chen Huabin, Mr. Shen Hongbo, Mr. Zhu Qin and Mr. Wong Kwan Kit.*

\* *For identification purpose only*